Alex Matter to head Novartis Institute for Tropical Diseases (VIRTUAL PRESS KIT)

August 28, 2003 06:00 ET | Source: Novartis Pharma AG Novartis Pharma AG

ENGLISH:

NITD Fact Sheet E.pdf

TB FAQ_E_August_2003.pdf

Dengue Fever FAQ_E_August_2003.pdf

Herrling CV_E_March_2003.pdf

Matter CV_E_Aug_2003.pdf

GERMAN:

NITD Fact Sheet D.pdf

TB FAQ_D_August_2003.pdf

Dengue Fever FAQ_D_August_2003.pdf

Herrling CV-G-March-2003.pdf

Matter CV_D_Aug_2003.pdf

FRENCH:

NITD Fact Sheet F.pdf

TB FAQ_F_August_2003.pdf

Dengue Fever FAQ_F_August_2003.pdf

Herrling CV-F-March-2003.pdf

Matter CV_F_Aug_2003.pdf

Recommended Reading

September 18, 2026 10:51 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based...
Read More
September 08, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...
Read More